In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
The future of Prescription Drug Affordability Boards (PDABs)
The effectiveness and impact of the UPL implementation for Enbrel will have a strong influence on how Maryland and other states proceed with their UPL...